Removing senescent cells from mouse brain ameliorates the effects of mutant human tau.
Believed to be an amyloid-lowering agent, the blood pressure drug did not help people at the dementia stage of disease.
The bill tops last year’s budget for the disease by $425 million.
Staufen1 may deplete certain mRNAs, precipitating the death of Purkinje and other neurons.
In DIAN, participants who are more physically active may also have slower disease progression.
Serial data establishes different trajectories for CSF t-tau and p-tau.
A large multicenter study confirms the tau PET ligand identifies AD at the dementia stage, but not so well at prodromal stages.
Ablating BACE1 in adult mice spares them from most problems found in germline knockouts. However, axons extending from newborn hippocampal neurons still lose their way.